Found: 75
Select item for more details and to access through your institution.
Optimal [<sup>18</sup>F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.266384
- By:
- Publication type:
- Article
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer.
- Published in:
- NPJ Breast Cancer, 2024, v. 10, n. 1, p. 1, doi. 10.1038/s41523-024-00675-x
- By:
- Publication type:
- Article
ASCO 2024: Personal Insights and a Look into the Future from an International Expert Group.
- Published in:
- 2024
- By:
- Publication type:
- Proceeding
Baseline CD4<sup>+</sup> and expansion of γδ T cells correlate with response to durvalumab in triple‐negative breast cancer patients.
- Published in:
- Clinical & Translational Medicine, 2024, v. 14, n. 4, p. 1, doi. 10.1002/ctm2.1617
- By:
- Publication type:
- Article
Characterization of Hormone Receptor and HER2 Status in Breast Cancer Using Mass Spectrometry Imaging.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 3, p. 2860, doi. 10.3390/ijms24032860
- By:
- Publication type:
- Article
Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
- Published in:
- Oncologist, 2023, v. 28, n. 1, p. 23, doi. 10.1093/oncolo/oyac205
- By:
- Publication type:
- Article
EVI1 expression in early-stage breast cancer patients treated with neoadjuvant chemotherapy.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.
- Published in:
- Frontiers in Oncology, 2022, v. 12, p. 1, doi. 10.3389/fonc.2022.886831
- By:
- Publication type:
- Article
Clonal Hematopoiesis–Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2022, v. 114, n. 4, p. 565, doi. 10.1093/jnci/djab231
- By:
- Publication type:
- Article
Antibody-Drug Conjugates for Breast Cancer.
- Published in:
- Oncology Research & Treatment, 2022, v. 45, n. 1/2, p. 26, doi. 10.1159/000521499
- By:
- Publication type:
- Article
Antibody-Drug Conjugates for Breast Cancer.
- Published in:
- Oncology Research & Treatment, 2022, v. 45, n. 1/2, p. 26, doi. 10.1159/000521499
- By:
- Publication type:
- Article
DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status.
- Published in:
- Clinical Epigenetics, 2021, v. 13, n. 1, p. 1, doi. 10.1186/s13148-021-01176-5
- By:
- Publication type:
- Article
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
- Published in:
- BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08656-0
- By:
- Publication type:
- Article
Correction to: TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
- Published in:
- 2021
- By:
- Publication type:
- corrected article
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Correction: MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
- Published in:
- 2021
- By:
- Publication type:
- Correction Notice
TGFB-induced factor homeobox 1 (TGIF) expression in breast cancer.
- Published in:
- BMC Cancer, 2021, v. 21, n. 1, p. 1, doi. 10.1186/s12885-021-08656-0
- By:
- Publication type:
- Article
Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?
- Published in:
- Breast Care, 2021, v. 16, n. 2, p. 115, doi. 10.1159/000514561
- By:
- Publication type:
- Article
Prognostic Cancer Gene Expression Signatures: Current Status and Challenges.
- Published in:
- Cells (2073-4409), 2021, v. 10, n. 3, p. 648, doi. 10.3390/cells10030648
- By:
- Publication type:
- Article
Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto-GBG 84 Trial.
- Published in:
- 2020
- By:
- Publication type:
- journal article
MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial.
- Published in:
- PLoS ONE, 2020, v. 15, n. 8, p. 1, doi. 10.1371/journal.pone.0238021
- By:
- Publication type:
- Article
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Development of novel FAP‐targeted radiotracers with improved tumor retention.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.118.224469
- By:
- Publication type:
- Article
Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 10, p. 1421, doi. 10.2967/jnumed.118.224469
- By:
- Publication type:
- Article
Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS + EG score.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 177, n. 2, p. 437, doi. 10.1007/s10549-019-05314-9
- By:
- Publication type:
- Article
Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2019, v. 145, n. 9, p. 2251, doi. 10.1007/s00432-019-02986-0
- By:
- Publication type:
- Article
Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial.
- Published in:
- Cancers, 2019, v. 11, n. 8, p. 1186, doi. 10.3390/cancers11081186
- By:
- Publication type:
- Article
ASCO 2019: New Results in Breast Cancer.
- Published in:
- 2019
- By:
- Publication type:
- Proceeding
Extracapsular Lymph Node Involvement in Ovarian Carcinoma.
- Published in:
- Cancers, 2019, v. 11, n. 7, p. 924, doi. 10.3390/cancers11070924
- By:
- Publication type:
- Article
Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation.
- Published in:
- Journal of Contemporary Brachytherapy, 2019, v. 11, n. 4, p. 312, doi. 10.5114/jcb.2019.87001
- By:
- Publication type:
- Article
Prophylaxis and Management of Skin Toxicities.
- Published in:
- Breast Care, 2019, v. 14, n. 2, p. 72, doi. 10.1159/000497232
- By:
- Publication type:
- Article
Luminal Metastatic Breast Cancer.
- Published in:
- Breast Care, 2019, v. 14, n. 2, p. 99, doi. 10.1159/000499440
- By:
- Publication type:
- Article
Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient.
- Published in:
- Breast Care, 2019, v. 14, n. 1, p. 53, doi. 10.1159/000492580
- By:
- Publication type:
- Article
Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor‐positive, human epidermal growth factor receptor 2‐negative locally advanced or metastatic breast cancer: Results of the single‐arm, phase IIIB 4EVER trial
- Published in:
- International Journal of Cancer, 2019, v. 144, n. 4, p. 877, doi. 10.1002/ijc.31738
- By:
- Publication type:
- Article
Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index.
- Published in:
- PLoS ONE, 2019, v. 14, n. 1, p. 1, doi. 10.1371/journal.pone.0211337
- By:
- Publication type:
- Article
Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer.
- Published in:
- International Journal of Molecular Sciences, 2019, v. 20, n. 2, p. 295, doi. 10.3390/ijms20020295
- By:
- Publication type:
- Article
What is the evidence for lymphadenectomy in presumed early ovarian cancer?
- Published in:
- 2019
- By:
- Publication type:
- journal article
COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 173, n. 1, p. 135, doi. 10.1007/s10549-018-4983-8
- By:
- Publication type:
- Article
Sustained prognostic impact of circulating tumor cell status and kinetics upon further progression of metastatic breast cancer.
- Published in:
- Breast Cancer Research & Treatment, 2019, v. 173, n. 1, p. 155, doi. 10.1007/s10549-018-4972-y
- By:
- Publication type:
- Article
Diagnosis of Li‐Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis.
- Published in:
- Human Mutation, 2018, v. 39, n. 12, p. 2040, doi. 10.1002/humu.23653
- By:
- Publication type:
- Article
Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 5, p. 848, doi. 10.1007/s10637-018-0562-4
- By:
- Publication type:
- Article
TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 10, p. 1899, doi. 10.1007/s00432-018-2706-5
- By:
- Publication type:
- Article
Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.
- Published in:
- Breast Cancer (13406868), 2018, v. 25, n. 3, p. 370, doi. 10.1007/s12282-017-0826-4
- By:
- Publication type:
- Article
Molecular Tumor Boards.
- Published in:
- 2018
- By:
- Publication type:
- Question & Answer
Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies.
- Published in:
- Breast Care, 2018, v. 13, n. 1, p. 22, doi. 10.1159/000486330
- By:
- Publication type:
- Article
A low-frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.
- Published in:
- International Journal of Cancer, 2018, v. 142, n. 4, p. 757, doi. 10.1002/ijc.31105
- By:
- Publication type:
- Article
Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials.
- Published in:
- Breast Cancer Research & Treatment, 2018, v. 167, n. 1, p. 59, doi. 10.1007/s10549-017-4480-5
- By:
- Publication type:
- Article
The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2018, v. 144, n. 1, p. 13, doi. 10.1007/s00432-017-2510-7
- By:
- Publication type:
- Article